Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of novel oral anticoagulant agents in venous thromboembolism.

Literature DB >> 28123977

Use of novel oral anticoagulant agents in venous thromboembolism.

Shivanshu Madan¹, Shenil Shah², Patrick Dale³, Sasan Partovi⁴, Sahil A Parikh⁵.

Abstract

New oral anticoagulants (NOAC) serve as alternatives for patients currently using warfarin for the prevention and treatment of venous thromboembolic (VTE) disease. This article provides a brief summary of the clinical use of these drugs as well as a review of the landmark clinical trials which evaluated described their safety and efficacy. As more data becomes available, a fundamental understanding of these medications will be vital to cardiovascular practitioners managing patients with VTE.

Entities: Chemical Disease Species

Keywords: Warfarin; apixaban; dabigatran; deep vein; edoxaban; pulmonary embolism (PE); rivaroxaban; thrombosis

Year: 2016 PMID： 28123977 PMCID： PMC5220203 DOI： 10.21037/cdt.2016.11.17

Source DB: PubMed Journal: Cardiovasc Diagn Ther ISSN： 2223-3652

46 in total

1. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.

Authors: Dagmar Kubitza; Michael Becka; Georg Wensing; Barbara Voith; Michael Zuehlsdorf
Journal: Eur J Clin Pharmacol Date: 2005-11-17 Impact factor: 2.953

2. Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.

Authors: Jeffrey I Weitz; William Semchuk; Alexander G G Turpie; William D Fisher; Cindy Kong; Antonio Ciaccia; John A Cairns
Journal: Clin Ther Date: 2015-10-16 Impact factor: 3.393

3. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Authors: Michael Rud Lassen; Alexander Gallus; Gary E Raskob; Graham Pineo; Dalei Chen; Luz Margarita Ramirez
Journal: N Engl J Med Date: 2010-12-23 Impact factor: 91.245

Review 4. Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.

Authors: Shivanshu Madan; Shenil Shah; Sasan Partovi; Sahil A Parikh
Journal: Cardiovasc Diagn Ther Date: 2014-08

5. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Authors: Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Philip Hornick
Journal: Lancet Date: 2010-03-06 Impact factor: 79.321

6. Idarucizumab for Dabigatran Reversal.

Authors: Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal: N Engl J Med Date: 2015-06-22 Impact factor: 91.245

7. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.

Authors: Sean D Pokorney; DaJuanicia N Simon; Laine Thomas; Gregg C Fonarow; Peter R Kowey; Paul Chang; Daniel E Singer; Jack Ansell; Rosalia G Blanco; Bernard Gersh; Kenneth W Mahaffey; Elaine M Hylek; Alan S Go; Jonathan P Piccini; Eric D Peterson
Journal: Am Heart J Date: 2015-04-01 Impact factor: 4.749

Use of novel oral anticoagulant agents in venous thromboembolism.

1. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.

2. Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.

3. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Review 4. Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.

5. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

6. Idarucizumab for Dabigatran Reversal.

7. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.

8. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

9. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Review 10. The epidemiology of venous thromboembolism.

1. Advanced venous imaging and image-guided venous interventions.

2. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.

3. Thromboembolism prophylaxis in orthopaedics: an update.